Lineage Cell Therapeutics (STU:BT3) FCF Yield % : -17.22 (As of Dec. 11, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Lineage Cell Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Lineage Cell Therapeutics's Trailing 12-Month Free Cash Flow is €-21.13 Mil, and Market Cap is €126.85 Mil. Therefore, Lineage Cell Therapeutics's FCF Yield % for today is -17.22%.

The historical rank and industry rank for Lineage Cell Therapeutics's FCF Yield % or its related term are showing as below:

STU:BT3' s FCF Yield % Range Over the Past 10 Years
Min: -38.15 Med: -13.69 Max: 2.84
Current: -17.22

During the past 13 years, the highest FCF Yield % of Lineage Cell Therapeutics was 2.84%. The lowest was -38.15%. And the median was -13.69%.

STU:BT3's FCF Yield % is ranked worse than
56.34% of 1507 companies
in the Biotechnology industry
Industry Median: -12.58 vs STU:BT3: -17.22

Lineage Cell Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was -156.09%.

Lineage Cell Therapeutics FCF Yield % Historical Data

The historical data trend for Lineage Cell Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics FCF Yield % Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

Get a 7-Day Free Trial

-29.04

-8.12

-5.67

0.31

-15.02

Lineage Cell Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Yield %	Get a 7-Day Free Trial															-10.08	-12.55	-9.30	-11.69	-13.90

Competitive Comparison of Lineage Cell Therapeutics's FCF Yield %

For the Biotechnology subindustry, Lineage Cell Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's FCF Yield % falls into.

Lineage Cell Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Lineage Cell Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-26.813	/	178.48674
	=	-15.02%

Lineage Cell Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-5.315	*	4	/	152.95797
	=	-13.90%

Lineage Cell Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Lineage Cell Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (STU:BT3) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

LCTX:USA LCTX:Israel BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics Headlines

No Headlines